Nicotinamide in the Treatment of Psoriasis

I

Isfahan University of Medical Sciences

Status and phase

Completed
Phase 3
Phase 2

Conditions

Psoriasis

Treatments

Drug: Calcipotriol plus Nicotinamide
Drug: Calcipotriol

Study type

Interventional

Funder types

Other

Identifiers

NCT01763424
390134

Details and patient eligibility

About

This study will determine if combination of topical calcipotriol and nicotinamide is more effective than calcipotriol alone in treatment of psoriasis.

Full description

Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments. Preliminary studies have shown that nicotinamide, which is a vitamin B derivative, is effective in the treatment of psoriasis. According to lack of data, we will investigate the beneficial effects of adding nicotinamide to calcipotriol for patients with mild to moderate psoriasis.

Enrollment

66 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women of 18 to 65 years old,
  • Mild to moderate psoriasis; patients must have had less than 15% of the involved body surface, symmetrical plaques (bilateral lesions) or two plaques at least 5 cm apart on the same side of the body with plaque size greater than 2 × 2 cm, but smaller than 15 × 15 cm.
  • Willingness to participate

Exclusion criteria

  • Those who used any medication or niacin and multi-vitamins two weeks, or anti-psoriatic systemic drugs or beta-blockers one month prior to the study,
  • Pregnant women,
  • Those with the history of renal, hematologic, liver and major psychiatric diseases,
  • Those with only scalp, nail, flexural, palmoplantar, or pustular psoriasis.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

66 participants in 2 patient groups

Calcipotriol
Active Comparator group
Description:
Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Treatment:
Drug: Calcipotriol
Calcipotriol plus Nicotinamide
Experimental group
Description:
Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Treatment:
Drug: Calcipotriol plus Nicotinamide

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems